InsidersTradesSigma
Total declarations
Company
▲ Purchases (5 ops.)
▼ Sales (2 ops.)
Insider track record
CEODisclosed buys
5
Disclosed sells
2
T+90 hit rate
33%
T+90 mean return
+3.6%
Across 6 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by BRYNJELSEN SEAN, Chief Executive Officer. Director active across 1 company, notably Eton Pharmaceuticals, Inc.. Cumulatively, 11 reports have been logged. Breakdown: 5 buys · 2 sells. Total volume traded: €3.4m. Activity tracked since 3 June 2021. The latest transaction was disclosed on 28 May 2026 (Cession). Regulator: SEC (Form 4). All data is free.
Declarations11 total
148 shares@ US$32.670.0005% mcap0.1% of flowCommon StockSEC:0001437749-26-018879:1
119,852 shares@ US$31.880.38% mcap87.4% of flowCommon StockSEC:0001437749-26-018879:0
5,015 shares@ US$15.3914.7% of flowCommon StockSEC:0001437749-26-001290
5,015 shares@ US$15.390.0079% mcap14.7% of flowCommon StockSEC:0001437749-26-001290:0
6,732 shares@ US$16.8321.6% of flowCommon StockSEC:0001437749-25-037741
6,732 shares@ US$16.830.012% mcap21.6% of flowCommon StockSEC:0001437749-25-037741:0
10,000 shares@ US$2.10420.6% of flowCommon StockSEC:0001493152-22-026629:0
Ideal exit: 19 Jun 2023 (T+270)
10,000 shares@ US$4.320.0045% mcap8.3% of flowCommon StockSEC:0001493152-21-020807:0
Ideal exit: 17 May 2022 (T+270)
10,000 shares@ US$4.321.0% of flowCommon StockSEC:0001493152-21-020807
Ideal exit: 17 May 2022 (T+270)
5,000 shares@ US$5.960.0030% mcap5.5% of flowCommon StockSEC:0001493152-21-013513:0
Ideal exit: 28 Feb 2022 (T+270)
5,000 shares@ US$5.960.7% of flowCommon StockSEC:0001493152-21-013513
Ideal exit: 28 Feb 2022 (T+270)
11 of 11 declarations
About BRYNJELSEN SEAN
Sean Brynjelsen is the President and CEO of Eton Pharmaceuticals, Inc. He leads the company by implementing strategies aimed at developing innovative pharmaceutical solutions and meeting market needs.
